Celsion Corp.’s CLSN shares have rallied almost 20% on Wednesday after ... the Zacks classified Medical-Biomed/Genetics industry so far this year. The stock has plunged 43.1% compared with the broader industry’s …
CLSN closed Tuesday's trading at $6.06, up 301.32%. In after-hours, the stock rose another 12.54% to $6.82. Shares of CytomX Therapeutics Inc. (CTMX) were up 35% in extended trading on Tuesday, following a strategic collaboration with …
If you want a Stock Review on CLSN, SRPT, BMRN or CTRV then come over to http://dailystocktracker.com/register/ …
Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here. …
Celsion Corporation CLSN announced results from phase Ib study — OVATION ... Investors cheered the news as the stock skyrocketed over 300% on Tuesday. In fact, shares of the company have surged 42.4% so far this year, outperforming …
Celsion Corp. CLSN provided an update on its GEN-1 immunotherapy pipeline ... Celsion is a Zacks Rank #3 (Hold) stock. Some better-ranked stocks in the health care sector include Actelion Ltd. ALIOF, Anika Therapeutics Inc. ANIK and …